Blau Farmacêutica S.A.

BOVESPA:BLAU3 Stock Report

Market Cap: R$2.3b

Blau Farmacêutica Dividends and Buybacks

Dividend criteria checks 2/6

Blau Farmacêutica is a dividend paying company with a current yield of 5.91% that is well covered by earnings.

Key information

5.9%

Dividend yield

0%

Buyback Yield

Total Shareholder Yield5.9%
Future Dividend Yield7.1%
Dividend Growth43.7%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per shareR$0.748
Payout ratio10%

Recent dividend and buyback updates

Recent updates

Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Dec 04
Does Blau Farmacêutica (BVMF:BLAU3) Have A Healthy Balance Sheet?

Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 07
Results: Blau Farmacêutica S.A. Exceeded Expectations And The Consensus Has Updated Its Estimates

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Nov 06
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 25% Share Price Surge Not Quite Adding Up

Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Aug 29
Blau Farmacêutica S.A.'s (BVMF:BLAU3) 31% Price Boost Is Out Of Tune With Earnings

Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Jun 28
Is Blau Farmacêutica (BVMF:BLAU3) A Risky Investment?

Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

Feb 01
Lacklustre Performance Is Driving Blau Farmacêutica S.A.'s (BVMF:BLAU3) 26% Price Drop

What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

May 14
What Does The Future Hold For Blau Farmacêutica S.A. (BVMF:BLAU3)? These Analysts Have Been Cutting Their Estimates

Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Feb 24
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next

Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Oct 14
Getting In Cheap On Blau Farmacêutica S.A. (BVMF:BLAU3) Is Unlikely

Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Aug 17
Robust Earnings May Not Tell The Whole Story For Blau Farmacêutica (BVMF:BLAU3)

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Whilst dividend payments have been stable, BLAU3 has been paying a dividend for less than 10 years.

Growing Dividend: BLAU3's dividend payments have increased, but the company has only paid a dividend for 3 years.


Dividend Yield vs Market

Blau Farmacêutica Dividend Yield vs Market
How does BLAU3 dividend yield compare to the market?
SegmentDividend Yield
Company (BLAU3)5.9%
Market Bottom 25% (BR)3.4%
Market Top 25% (BR)10.1%
Industry Average (Biotechs)2.5%
Analyst forecast (BLAU3) (up to 3 years)7.1%

Notable Dividend: BLAU3's dividend (5.91%) is higher than the bottom 25% of dividend payers in the BR market (3.4%).

High Dividend: BLAU3's dividend (5.91%) is low compared to the top 25% of dividend payers in the BR market (10.14%).


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (9.9%), BLAU3's dividend payments are thoroughly covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its high cash payout ratio (151.2%), BLAU3's dividend payments are not well covered by cash flows.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 02:01
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Blau Farmacêutica S.A. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Marcio OsakoBradesco S.A. Corretora de Títulos e Valores Mobiliários
Frederico MendesBradesco S.A. Corretora de Títulos e Valores Mobiliários
Samuel Campos AlvesBTG Pactual